PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
Authors
Keywords
MET receptor tyrosine kinase, PI3K pathway, <em class=EmphasisTypeItalic >PIK3CA</em> mutations, Resistance mechanisms, Head and neck cancer
Journal
Molecular Cancer
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-05-22
DOI
10.1186/s12943-017-0660-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mapping the Pathways of Resistance to Targeted Therapies
- (2015) K. C. Wood CANCER RESEARCH
- KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells
- (2015) Dominic Leiser et al. Molecular Oncology
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside
- (2014) A. Avan et al. CURRENT MEDICINAL CHEMISTRY
- mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
- (2014) Zhiyong Wang et al. JNCI-Journal of the National Cancer Institute
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
- (2014) Christiane R. Maroun et al. PHARMACOLOGY & THERAPEUTICS
- MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
- (2014) Rajani Kanteti et al. PLoS One
- Met in Urological Cancers
- (2014) Yasuyoshi Miyata et al. Cancers
- Mutationally Activated PIK3CAH1047R Cooperates with BRAFV600E to Promote Lung Cancer Progression
- (2013) C. L. Trejo et al. CANCER RESEARCH
- Targeting the MET gene for the treatment of non-small-cell lung cancer
- (2013) F. Gelsomino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
- (2013) Michaela Medová et al. MOLECULAR CANCER THERAPEUTICS
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy
- (2013) Cynthia Brito Lins Pereira et al. PLoS One
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
- (2013) D S Meyer et al. Oncogenesis
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
- (2012) Natalie R. Young et al. Molecular Oncology
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
- (2011) D. V. T. Catenacci et al. Cancer Discovery
- Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
- (2010) F Di Fiore et al. BRITISH JOURNAL OF CANCER
- New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors
- (2010) L. F. Chen et al. CLINICAL CANCER RESEARCH
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
- (2010) V. Vaira et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274
- (2009) Yitzhak Zimmer et al. CANCER LETTERS
- The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
- (2009) T. Y. Seiwert et al. CANCER RESEARCH
- HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
- (2009) L. M. Knowles et al. CLINICAL CANCER RESEARCH
- The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
- (2009) M. Ray et al. ONCOLOGIST
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search